Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 59


"You do not get cancer by chance": Communicating the role of environmental causes in cancer diseases and the risk of a "guilt rhetoric".

Oliveri S, Scotto L, Ongaro G, Triberti S, Guiddi P, Pravettoni G.

Psychooncology. 2019 Dec;28(12):2422-2424. doi: 10.1002/pon.5224. Epub 2019 Oct 21. No abstract available.


Oral 5-azacytidine and romidepsin exhibit marked activity in patients with PTCL: a multicenter phase 1 study.

O'Connor OA, Falchi L, Lue JK, Marchi E, Kinahan C, Sawas A, Deng C, Montanari F, Amengual JE, Kim HA, Rada AM, Khan K, Jacob AT, Malanga M, Francescone MM, Nandakumar R, Soderquist CR, Park DC, Bhagat G, Cheng B, Risueño A, Menezes D, Shustov AR, Sokol L, Scotto L.

Blood. 2019 Oct 24;134(17):1395-1405. doi: 10.1182/blood.2019001285.


IL-22-Independent Protection from Colitis in the Absence of Nkx2.3 Transcription Factor in Mice.

Kellermayer Z, Vojkovics D, Dakah TA, Bodó K, Botz B, Helyes Z, Berta G, Kajtár B, Schippers A, Wagner N, Scotto L, O'Connor OA, Arnold HH, Balogh P.

J Immunol. 2019 Mar 15;202(6):1833-1844. doi: 10.4049/jimmunol.1801117. Epub 2019 Jan 30.


Implementation of a Needs-Based, Online Feedback Tool for Anesthesia Residents With Subsequent Mapping of the Feedback to the ACGME Milestones.

Tanaka P, Bereknyei Merrell S, Walker K, Zocca J, Scotto L, Bogetz AL, Macario A.

Anesth Analg. 2017 Feb;124(2):627-635. doi: 10.1213/ANE.0000000000001647.


Mechanisms of Acquired Drug Resistance to the HDAC6 Selective Inhibitor Ricolinostat Reveals Rational Drug-Drug Combination with Ibrutinib.

Amengual JE, Prabhu SA, Lombardo M, Zullo K, Johannet PM, Gonzalez Y, Scotto L, Serrano XJ, Wei Y, Duong J, Nandakumar R, Cremers S, Verma A, Elemento O, O'Connor OA.

Clin Cancer Res. 2017 Jun 15;23(12):3084-3096. doi: 10.1158/1078-0432.CCR-16-2022. Epub 2016 Dec 19.


Silencing c-Myc translation as a therapeutic strategy through targeting PI3Kδ and CK1ε in hematological malignancies.

Deng C, Lipstein MR, Scotto L, Jirau Serrano XO, Mangone MA, Li S, Vendome J, Hao Y, Xu X, Deng SX, Realubit RB, Tatonetti NP, Karan C, Lentzsch S, Fruman DA, Honig B, Landry DW, O'Connor OA.

Blood. 2017 Jan 5;129(1):88-99. doi: 10.1182/blood-2016-08-731240. Epub 2016 Oct 26.


Impact of an Innovative Classroom-Based Lecture Series on Residents' Evaluations of an Anesthesiology Rotation.

Tanaka P, Yanez D, Lemmens H, Djurdjulov A, Scotto L, Borg L, Walker K, Bereknyei Merrell S, Macario A.

Anesthesiol Res Pract. 2016;2016:8543809. doi: 10.1155/2016/8543809. Epub 2016 Feb 17.


Epigenetic inactivation of TRAIL decoy receptors at 8p12-21.3 commonly deleted region confers sensitivity to Apo2L/trail-Cisplatin combination therapy in cervical cancer.

Narayan G, Xie D, Ishdorj G, Scotto L, Mansukhani M, Pothuri B, Wright JD, Kaufmann AM, Schneider A, Arias-Pulido H, Murty VV.

Genes Chromosomes Cancer. 2016 Feb;55(2):177-89. doi: 10.1002/gcc.22325. Epub 2015 Nov 6.


The combination of hypomethylating agents and histone deacetylase inhibitors produce marked synergy in preclinical models of T-cell lymphoma.

Marchi E, Zullo KM, Amengual JE, Kalac M, Bongero D, McIntosh CM, Fogli LK, Rossi M, Zinzani PL, Pileri SA, Piccaluga PP, Fuligni F, Scotto L, O'Connor OA.

Br J Haematol. 2015 Oct;171(2):215-226. doi: 10.1111/bjh.13566. Epub 2015 Jul 20.


Dual Targeting of Protein Degradation Pathways with the Selective HDAC6 Inhibitor ACY-1215 and Bortezomib Is Synergistic in Lymphoma.

Amengual JE, Johannet P, Lombardo M, Zullo K, Hoehn D, Bhagat G, Scotto L, Jirau-Serrano X, Radeski D, Heinen J, Jiang H, Cremers S, Zhang Y, Jones S, O'Connor OA.

Clin Cancer Res. 2015 Oct 15;21(20):4663-75. doi: 10.1158/1078-0432.CCR-14-3068. Epub 2015 Jun 26.


Aurora A Kinase Inhibition Selectively Synergizes with Histone Deacetylase Inhibitor through Cytokinesis Failure in T-cell Lymphoma.

Zullo KM, Guo Y, Cooke L, Jirau-Serrano X, Mangone M, Scotto L, Amengual JE, Mao Y, Nandakumar R, Cremers S, Duong J, Mahadevan D, O'Connor OA.

Clin Cancer Res. 2015 Sep 15;21(18):4097-109. doi: 10.1158/1078-0432.CCR-15-0033. Epub 2015 Apr 15.


Preclinical pharmacologic evaluation of pralatrexate and romidepsin confirms potent synergy of the combination in a murine model of human T-cell lymphoma.

Jain S, Jirau-Serrano X, Zullo KM, Scotto L, Palermo CF, Sastra SA, Olive KP, Cremers S, Thomas T, Wei Y, Zhang Y, Bhagat G, Amengual JE, Deng C, Karan C, Realubit R, Bates SE, O'Connor OA.

Clin Cancer Res. 2015 May 1;21(9):2096-106. doi: 10.1158/1078-0432.CCR-14-2249. Epub 2015 Feb 12.


PCDH10 promoter hypermethylation is frequent in most histologic subtypes of mature lymphoid malignancies and occurs early in lymphomagenesis.

Narayan G, Xie D, Freddy AJ, Ishdorj G, Do C, Satwani P, Liyanage H, Clark L, Kisselev S, Nandula SV, Scotto L, Alobeid B, Savage D, Tycko B, O'Connor OA, Bhagat G, Murty VV.

Genes Chromosomes Cancer. 2013 Nov;52(11):1030-41. doi: 10.1002/gcc.22098. Epub 2013 Aug 9.


Sirtuin and pan-class I/II deacetylase (DAC) inhibition is synergistic in preclinical models and clinical studies of lymphoma.

Amengual JE, Clark-Garvey S, Kalac M, Scotto L, Marchi E, Neylon E, Johannet P, Wei Y, Zain J, O'Connor OA.

Blood. 2013 Sep 19;122(12):2104-13. doi: 10.1182/blood-2013-02-485441. Epub 2013 Aug 2.


Murine models in mantle cell lymphoma.

Zullo K, Amengual JE, O'Connor OA, Scotto L.

Best Pract Res Clin Haematol. 2012 Jun;25(2):153-63. doi: 10.1016/j.beha.2012.04.009. Epub 2012 May 30. Review.


Development and characterization of a novel CD19CherryLuciferase (CD19CL) transgenic mouse for the preclinical study of B-cell lymphomas.

Scotto L, Kruithof-de Julio M, Paoluzzi L, Kalac M, Marchi E, Buitrago JB, Amengual J, Shen MM, O'Connor OA.

Clin Cancer Res. 2012 Jul 15;18(14):3803-11. doi: 10.1158/1078-0432.CCR-11-2588. Epub 2012 May 15.


Fbxw7α- and GSK3-mediated degradation of p100 is a pro-survival mechanism in multiple myeloma.

Busino L, Millman SE, Scotto L, Kyratsous CA, Basrur V, O'Connor O, Hoffmann A, Elenitoba-Johnson KS, Pagano M.

Nat Cell Biol. 2012 Mar 4;14(4):375-85. doi: 10.1038/ncb2463.


HDAC inhibitors and decitabine are highly synergistic and associated with unique gene-expression and epigenetic profiles in models of DLBCL.

Kalac M, Scotto L, Marchi E, Amengual J, Seshan VE, Bhagat G, Ulahannan N, Leshchenko VV, Temkin AM, Parekh S, Tycko B, O'Connor OA.

Blood. 2011 Nov 17;118(20):5506-16. doi: 10.1182/blood-2011-02-336891. Epub 2011 Jul 19.


Pralatrexate is synergistic with the proteasome inhibitor bortezomib in in vitro and in vivo models of T-cell lymphoid malignancies.

Marchi E, Paoluzzi L, Scotto L, Seshan VE, Zain JM, Zinzani PL, O'Connor OA.

Clin Cancer Res. 2010 Jul 15;16(14):3648-58. doi: 10.1158/1078-0432.CCR-10-0671. Epub 2010 May 25.


Romidepsin and belinostat synergize the antineoplastic effect of bortezomib in mantle cell lymphoma.

Paoluzzi L, Scotto L, Marchi E, Zain J, Seshan VE, O'Connor OA.

Clin Cancer Res. 2010 Jan 15;16(2):554-65. doi: 10.1158/1078-0432.CCR-09-1937. Epub 2010 Jan 12.


Protocadherin PCDH10, involved in tumor progression, is a frequent and early target of promoter hypermethylation in cervical cancer.

Narayan G, Scotto L, Neelakantan V, Kottoor SH, Wong AH, Loke SL, Mansukhani M, Pothuri B, Wright JD, Kaufmann AM, Schneider A, Arias-Pulido H, Tao Q, Murty VV.

Genes Chromosomes Cancer. 2009 Nov;48(11):983-92. doi: 10.1002/gcc.20703.


The anti-histaminic cyproheptadine synergizes the antineoplastic activity of bortezomib in mantle cell lymphoma through its effects as a histone deacetylase inhibitor.

Paoluzzi L, Scotto L, Marchi E, Seshan VE, O'Connor OA.

Br J Haematol. 2009 Sep;146(6):656-9. doi: 10.1111/j.1365-2141.2009.07797.x. Epub 2009 Jul 8.


The BH3-only mimetic ABT-737 synergizes the antineoplastic activity of proteasome inhibitors in lymphoid malignancies.

Paoluzzi L, Gonen M, Bhagat G, Furman RR, Gardner JR, Scotto L, Gueorguiev VD, Heaney ML, Manova K, O'Connor OA.

Blood. 2008 Oct 1;112(7):2906-16. doi: 10.1182/blood-2007-12-130781. Epub 2008 Jun 30.


Successful aging in a 70-year-old man with down syndrome: a case study.

Krinsky-McHale SJ, Devenny DA, Gu H, Jenkins EC, Kittler P, Murty VV, Schupf N, Scotto L, Tycko B, Urv TK, Ye L, Zigman WB, Silverman W.

Intellect Dev Disabil. 2008 Jun;46(3):215-28. doi: 10.1352/2008.46:215-228.


Integrative genomics analysis of chromosome 5p gain in cervical cancer reveals target over-expressed genes, including Drosha.

Scotto L, Narayan G, Nandula SV, Subramaniyam S, Kaufmann AM, Wright JD, Pothuri B, Mansukhani M, Schneider A, Arias-Pulido H, Murty VV.

Mol Cancer. 2008 Jun 17;7:58. doi: 10.1186/1476-4598-7-58.


Identification of copy number gain and overexpressed genes on chromosome arm 20q by an integrative genomic approach in cervical cancer: potential role in progression.

Scotto L, Narayan G, Nandula SV, Arias-Pulido H, Subramaniyam S, Schneider A, Kaufmann AM, Wright JD, Pothuri B, Mansukhani M, Murty VV.

Genes Chromosomes Cancer. 2008 Sep;47(9):755-65. doi: 10.1002/gcc.20577.


Assessment of CD4+ T cells specific for the tumor antigen SSX-1 in cancer-free individuals.

Godefroy E, Wang Y, Souleimanian NE, Scotto L, Stevanovic S, Chen YT, Valmori D, Ayyoub M.

Cancer Immunol Immunother. 2007 Aug;56(8):1183-92. Epub 2006 Dec 22.


Epitope clustering in regions undergoing efficient proteasomal processing defines immunodominant CTL regions of a tumor antigen.

Valmori D, Lévy F, Godefroy E, Scotto L, Souleimanian NE, Karbach J, Tosello V, Hesdorffer CS, Old LJ, Jager E, Ayyoub M.

Clin Immunol. 2007 Feb;122(2):163-72. Epub 2006 Oct 24.


Identification of two Melan-A CD4+ T cell epitopes presented by frequently expressed MHC class II alleles.

Godefroy E, Scotto L, Souleimanian NE, Ritter G, Old LJ, Jotereau F, Valmori D, Ayyoub M.

Clin Immunol. 2006 Oct;121(1):54-62. Epub 2006 Jun 30.


Recombinant Ig-like transcript 3-Fc modulates T cell responses via induction of Th anergy and differentiation of CD8+ T suppressor cells.

Kim-Schulze S, Scotto L, Vlad G, Piazza F, Lin H, Liu Z, Cortesini R, Suciu-Foca N.

J Immunol. 2006 Mar 1;176(5):2790-8.


Regulation of ILT3 gene expression by processing of precursor transcripts in human endothelial cells.

Kim-Schulze S, Seki T, Vlad G, Scotto L, Fan J, Colombo PC, Liu J, Cortesini R, Suciu-Foca N.

Am J Transplant. 2006 Jan;6(1):76-82.


A phenotype based approach for the immune monitoring of NY-ESO-1-specific CD4+ T cell responses in cancer patients.

Ayyoub M, Souleimanian NE, Godefroy E, Scotto L, Hesdorffer CS, Old LJ, Valmori D.

Clin Immunol. 2006 Feb-Mar;118(2-3):188-94. Epub 2005 Dec 20.


Rat CD8+ FOXP3+ T suppressor cells mediate tolerance to allogeneic heart transplants, inducing PIR-B in APC and rendering the graft invulnerable to rejection.

Liu J, Liu Z, Witkowski P, Vlad G, Manavalan JS, Scotto L, Kim-Schulze S, Cortesini R, Hardy MA, Suciu-Foca N.

Transpl Immunol. 2004 Dec;13(4):239-47.


Molecular characterization of allospecific T suppressor and tolerogenic dendritic cells: review.

Suciu-Foca N, Manavalan JS, Scotto L, Kim-Schulze S, Galluzzo S, Naiyer AJ, Fan J, Vlad G, Cortesini R.

Int Immunopharmacol. 2005 Jan;5(1):7-11. Review.


Overlap between molecular markers expressed by naturally occurring CD4+CD25+ regulatory T cells and antigen specific CD4+CD25+ and CD8+CD28- T suppressor cells.

Scotto L, Naiyer AJ, Galluzzo S, Rossi P, Manavalan JS, Kim-Schulze S, Fang J, Favera RD, Cortesini R, Suciu-Foca N.

Hum Immunol. 2004 Nov;65(11):1297-306.


Role of regulatory and suppressor T-cells in the induction of ILT3+ ILT4+ tolerogenic endothelial cells in organ allografts.

Cortesini NS, Colovai AI, Manavalan JS, Galluzzo S, Naiyer AJ, Liu J, Vlad G, Kim-Schulze S, Scotto L, Fan J, Cortesini R.

Transpl Immunol. 2004 Sep-Oct;13(2):73-82. Review. No abstract available.


Alloantigen specific CD8+CD28- FOXP3+ T suppressor cells induce ILT3+ ILT4+ tolerogenic endothelial cells, inhibiting alloreactivity.

Manavalan JS, Kim-Schulze S, Scotto L, Naiyer AJ, Vlad G, Colombo PC, Marboe C, Mancini D, Cortesini R, Suciu-Foca N.

Int Immunol. 2004 Aug;16(8):1055-68. Epub 2004 Jun 28.


New mutations and protein variants of NBS1 are identified in cancer cell lines.

Tessitore A, Biordi L, Flati V, Toniato E, Marchetti P, Ricevuto E, Ficorella C, Scotto L, Giannini G, Frati L, Masciocchi C, Tombolini V, Gulino A, Martinotti S.

Genes Chromosomes Cancer. 2003 Feb;36(2):198-204.


An apparent interlocus gene conversion-like event at a putative tumor suppressor gene locus on human chromosome 6q27 in a Burkitt's lymphoma cell line.

Hauptschein RS, Gaidano G, Rao PH, Scotto L, Edwards YH, Chaganti RS, Dalla-Favera R.

DNA Res. 2000 Aug 31;7(4):261-72.


Analysis of a 69-kb contiguous genomic sequence at a putative tumor suppressor gene locus on human chromosome 6q27.

Qu XY, Hauptschein RS, Rzhetsky A, Scotto L, Chien MC, Ye X, Frigeri F, Rao PH, Pasqualucci L, Gamberi B, Deaven LL, Zhang P, Chaganti RS, Dalla-Favera R, Russo JJ.

DNA Seq. 1998;9(4):189-204.


Cloning and mapping of human chromosome 6q26-q27 deleted in B-cell non-Hodgkin lymphoma and multiple tumor types.

Hauptschein RS, Gamberi B, Rao PH, Frigeri F, Scotto L, Venkatraj VS, Gaidano G, Rutner T, Edwards YH, Chaganti RS, Dalla-Favera R.

Genomics. 1998 Jun 1;50(2):170-86.


Post-transcriptional control regulates transforming growth factor alpha in the human carcinoma KB cell line.

Nicolini G, Miloso M, Moroni MC, Beguinot L, Scotto L.

J Biol Chem. 1996 Nov 22;271(47):30290-6.


Antisense epidermal growth factor receptor transfection impairs the proliferative ability of human rhabdomyosarcoma cells.

De Giovanni C, Landuzzi L, Frabetti F, Nicoletti G, Griffoni C, Rossi I, Mazzotti M, Scotto L, Nanni P, Lollini PL.

Cancer Res. 1996 Sep 1;56(17):3898-901.


Epidermal growth factor receptor interaction with clathrin adaptors is mediated by the Tyr974-containing internalization motif.

Sorkin A, Mazzotti M, Sorkina T, Scotto L, Beguinot L.

J Biol Chem. 1996 Jun 7;271(23):13377-84.


Binding of AP-1/CREB proteins and of MDBP to contiguous sites downstream of the human TGF-beta 1 gene.

Asiedu CK, Scotto L, Assoian RK, Ehrlich M.

Biochim Biophys Acta. 1994 Sep 13;1219(1):55-63.


Supplemental Content

Loading ...
Support Center